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ABSTRACT: Human induced pluripotent stem cells (hiPSC) possess significant
therapeutic potential due to their high self-renewal capability and potential to
differentiate into specialized cells such as cardiomyocytes. However, generated hiPSC-
derived cardiomyocytes (hiPSC-CM) are still immature, with phenotypic and
functional features resembling the fetal rather than their adult counterparts, which
limits their application in cell-based therapies, in vitro cardiac disease modeling, and
drug cardiotoxicity screening. Recent discoveries have demonstrated the potential of
the extracellular matrix (ECM) as a critical regulator in development, homeostasis, and
injury of the cardiac microenvironment. Within this context, this work aimed to assess
the impact of human cardiac ECM in the phenotype and maturation features of
hiPSC-CM. Human ECM was isolated from myocardium tissue through a physical
decellularization approach. The cardiac tissue decellularization process reduced DNA
content significantly while maintaining ECM composition in terms of sulfated
glycosaminoglycans (s-GAG) and collagen content. These ECM particles were successfully incorporated in three-dimensional (3D)
hiPSC-CM aggregates (CM+ECM) with no impact on viability and metabolic activity throughout 20 days in 3D culture conditions.
Also, CM+ECM aggregates displayed organized and longer sarcomeres, with improved calcium handling when compared to hiPSC-
CM aggregates. This study shows that human cardiac ECM functionalization of hiPSC-based cardiac tissues improves cardiomyocyte
maturation. The knowledge generated herein provides essential insights to streamline the application of ECM in the development of
hiPSC-based therapies targeting cardiac diseases.
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1. INTRODUCTION
The adult human heart has a negligible capacity to regenerate,
with a cardiomyocyte renewal rate estimated at 1% each year,
which declines with age.1 Even if adult cardiomyocytes isolated
from cardiac biopsies were an unlimited cell source for cardiac
research, dedifferentiation and loss of viability in vitro soon
after isolation discourage their use.2 Although adult cardiac
tissue may be kept under electromechanical stimuli, noticeable
alterations at the structural, mechanical, and gene expression
levels are still detectable.3 Therefore, cardiac research uses
other platforms, such as animal models and ion-channel
overexpressing cell lines, even though they present over-
whelming physiological differences relative to human cardiac
tissue. Because of their high self-renewal ability and capacity to
differentiate into any cell type of the human body, including
cardiac cell lineages, human induced pluripotent stem cells
(hiPSC) have been establishing a new paradigm in cardiac
research. Their capability to generate high numbers of patient-
specific and functional cardiomyocytes makes them a powerful
cell source to be used not only in personalized cell therapy4 but
also in drug screening5 and disease modeling.6 In the past
decade, much effort has been made to develop improved
protocols for the generation of hiPSC-CM in high yields and
purity with electrophysiological and contractile properties.7
Despite their promising features, generated hiPSC-CM still
maintain an immature state following differentiation.8 The
fetal-like phenotype, structure, and functionality of these cells
dramatically limit their translational use, and thus, several
strategies are under evaluation to allow these cells to mature
and resemble those found in an adult human heart. Within this
context, the impact of critical environmental and biological
factors, including (i) mechanical9,10 and electrical stimuli,10−12
(ii) co-culture strategies with non-myocytes cells,13,14 (iii)
metabolic modulation,15,16 (iv) hormonal treatment,17,18 and
(v) 3D culturing approaches,19−21 on hiPSC-CM maturation
have been reported. The most advanced strategies reported to
date have been successful in even emulating certain
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cardiomyocyte features that only develop after birth such as a
vast network of T-tubules that ensure calcium homeostasis and
a rapid excitation-contraction coupling (ECC), adequate
inotropic response, reliance on oxidative metabolism through
β-oxidation, a positive force-frequency relationship (FFR), and
greater contractile force to ensure pump function.10,12,20 To
obtain such mature features, hiPSC-CM are typically
assembled into engineered heart tissues (EHT) or complex
3D scaffolding materials, which compromises their high-
throughput performance. Furthermore, growing these tissues
requires a suitable biomaterial, most commonly single-protein
extracellular matrix (ECM)-derived products derived from
animal tissue (e.g., rat-tail collagen), proteins that have little
presence in the fetal or adult heart (e.g., fibrin), or even more
complex matrices subjected to batch-to-batch variability (e.g.,
Matrigel). Despite their adequate biological activity, these
biomaterials are far from providing the same biochemical and
biophysical cues present in the native cardiac ECM. Never-
theless, the potential of engineered functional biomaterials that
mimic the ECM has been widely explored in the literature.
When combined with stem cells or their derivatives, these
specialized materials can enable robust biological mimicry for
efficient tissue engineering.22−24
The cardiac ECM is a complex fibrillar protein network of
glycosaminoglycans (GAG), and proteoglycans, arranged in a
precise 3D framework that accommodates cardiomyocytes,
fibroblasts, endothelial cells, and other non-myocyte cells in
the heart, besides providing an ideal milieu for multiple cell-
receptor and growth factors.25 Both in vivo and in vitro studies
suggest that the cardiac ECM could have a significant role in
cell/tissue differentiation, development, and maturation. For
instance, the ECM protein agrin triggers mild cardiomyocyte
differentiation and proliferation in mice, besides being
fundamental in regeneration at neonatal stages.26 In addition,
the effect of laminin is well documented regarding develop-
ment and regeneration,27 and particularly laminin was
identified as a potent enhancer of cardiomyocyte maturation.28
Decellularized mouse heart ECM further aids the differ-
entiation of embryonic stem cells toward cardiomyocytes.29
Moreover, the age (fetal versus adult) and geometry (2D
versus 3D) of decellularized porcine heart ECM modulate the
mechanical properties as well as fiber architecture and were
shown to influence hiPSC-CM maturation at gene and protein
expression levels.30 Although human ECM isolated from
perfusion-decellularized hearts could sustain contracting
hiPSC-CM into bundle-like tissues,31 the authors did not
evaluate its impact on the cells’ maturation profile.
Herein, we evaluated the effect of ECM of adult human
myocardium tissue isolated from healthy donors, in the
phenotype and maturation features of hiPSC-CM aggregated
into a 3D microtissue. Human myocardial tissue was physically
processed, without detergents or enzymes, into homogeneous
ECM particles that were characterized at the physical and
biochemical level and, for the first time, incorporated in the 3D
hiPSC-derived cardiac aggregate model, developed previously
by our group.19 These ECM functionalized hiPSC-CM
aggregates were cultured for 20 days, and their phenotype,
structure, and functionality were evaluated and compared with
hiPSC-CM aggregates. We believe that our approach is
innovative by using cryomilled human ECM to mature
hiPSC-CM in 3D aggregates. Furthermore, this approach
presents several advantages compared with hydrogels with
solubilized ECM, including the maintenance of the cardiac
tissue’s micromechanical and compositional properties.
2. MATERIALS AND METHODS
2.1. Human Cardiac Tissue Processing. Human heart tissue
biopsies were provided by Coimbra Hospital University Centre
(CHUC, Coimbra, Portugal) following the regulations of the tissue
bank and the approval of the Ethics Committee of Faculty of
Medicine of the University of Coimbra (CE-022/2017). Left
ventricular myocardial tissues were harvested, by the hospital unit,
from the heart of donors (n = 3) with no pathology associated, that
were not suitable for transplantation, after specific consent was
obtained; donor ages were 67 (female), 67 (female), and 69 (male).
Shortly after harvest, myocardial tissue samples were stored at −80
°C. In this work, a physical-based protocol was applied for
decellularization of the myocardial tissue. Briefly, myocardial tissue
samples were thawed, pooled, and sectioned into small pieces using
scalpels, in aseptic conditions. The tissue pieces were then further
fragmented using a manual cryomilling method, as described further.
The tissue pieces were rinsed in Dulbecco’s phosphate-buffered saline
(DPBS, Thermo Fisher Scientific), followed by a freezing step in
liquid nitrogen. The samples were milled aseptically using a mortar
and pestle to produce a fine powder. This cryomilling was repeated
three times, and the resulting material was washed and recovered with
DPBS and stored at −80 °C. ECM particles were then freeze-dried
(freeze-drier Labconco Triad) overnight and stored at −80 °C.
2.2. Characterization of Human Cardiac ECM. 2.2.1. Histol-
ogy: ECM Particles. The ECM particles were fixed in 4% (w/v)
buffered paraformaldehyde (PFA, Sigma-Aldrich) for 18 h at 4 °C,
washed twice in DPBS, pelleted, and embedded in 2% (w/v) high
melting temperature agarose (Lonza). Samples were dehydrated at
room temperature (RT, 20−22 °C), paraffin-embedded, and
sectioned (3 μm thickness) on a rotary microtome (RM 2135,
Leica). Sections were subjected to standardized deparaffinization
procedure and then stained with hematoxylin and eosin (H&E,
Sigma-Aldrich) and Masson’s Trichrome with Aniline Blue (MT, IHC
World), according to the manufacturers’ instructions. Histological
images were digitalized in a NanoZoomer SQ whole slide scanner
(Hamamatsu Photonics) and analyzed with NDP.view open-source
software (NDP.view v.2.7.43, Hamamatsu Photonics).
2.2.2. Biochemical Analysis: dsDNA and ECM Components
Quantification. Double-stranded DNA (dsDNA) and key ECM
components were quantified in decellularized ECM. Decellularized
samples were digested in 500 μL of papain solution (125 μg/mL in
0.1 M sodium acetate, 5 mM cysteine-HCl, 0.05 M EDTA, pH 6.0, all
from Sigma-Aldrich) for 20 h at 60 °C under agitation. Native tissue
samples with similar wet weight were also digested. The dsDNA
content was determined using the Quanti-iTPicoGreen assay
(Thermo Fisher Scientific) according to the manufacturer’s
instructions. The fluorescent intensity was measured in the microplate
reader Infinite200 PRO (NanoQuant, Tecan Trading AG). The
sulfated glycosaminoglycans (s-GAG) content was quantified using
the 1,9-dimethyl methylene blue assay (Glycosaminoglycan-GAG
Assay Blyscan, Biocolor), and collagen content (soluble, insoluble,
and total) was determined via a commercial kit (Sircol Collagen
Assay, Biocolor). Sample absorbance was measured in the plate reader
Infinite200 PRO. Data were expressed as the measured component
mass normalized for tissue sample wet weight.
2.2.3. Scanning Electron Microscopy and Energy-Dispersive X-
ray Spectroscopy of ECM Particles. ECM particles were fixed in 4%
(w/v) PFA (4 °C for 18 h), followed by three washes with DPBS for
10 min at RT. Samples were dried in adhesive carbon substrates (12
mm, Agar Scientific), sputter-coated with a 15 nm Au/Pd film, and
visualized in a tabletop scanning electron microscope with energy-
dispersive X-ray spectroscopy capability (SEM, Hitachi TM3030Plus;
EDS, Bruker QUANTAX) operated in backscattered electron imaging
mode at an accelerating voltage of 15 keV. SEM images of ECM
particles were analyzed in ImageJ open-source software (Rasband,
W.S., ImageJ, U.S. National Institutes of Health) to estimate particle
mean Feret diameter.
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2.2.4. Atomic Force Microscopy of ECM Particles. Hydrated ECM
particles were dried in a vacuum chamber and immobilized with
double side tape. Atomic force microscopy (AFM) analysis was done
with an Asylum Research MFP-3D Standalone system operated in AC
(alternate contact) mode in air, using commercially available silicon
probes (Olympus AC160TS; k = 26 N/m; f 0 = 300 kHz). The
resulting topographs were low-order plane fitted before being
exported as images using Gwyddion software.
2.3. hiPSC Culture. 2.3.1. Expansion and Differentiation of
hiPSC into Cardiomyocytes. The hiPSC line DF19−9−11T.H
(WiCell) was used in this study, and cells were propagated and
differentiated into cardiomyocytes according to the protocol
developed by our group.19 The hiPSC were propagated in Matrigel-
coated (Corning) plates as previously described.19,32 At day 8 of
differentiation, cells, designated as early stage cardiomyocytes, were
detached with TrypLE Select (Thermo Fisher Scientific) as reported
elsewhere.19,32
2.3.2. Generation of ECM Functionalized hiPSC-CM Aggregates.
The ECM particles were immersed in 70% (v/v) ethanol for 30 min
at RT and treated with ultraviolet light (15 min). After being
sterilized, ECM particles were rinsed with DPBS and air-dried
aseptically. Cells harvested at day 8 of differentiation were
resuspended in RPMI medium supplemented with B27 with insulin
(RPMI/B27 plus insulin, Thermo Fisher Scientific), containing 1%
(w/v) ECM particles (corresponding to 3 ng of ECM per cell). The
cell aggregates functionalized with ECM particles (hereafter
designated as CM+ECM aggregates) were obtained by forced
aggregation in AggreWell400Ex (Stem Cell Technologies), and
cultured in orbital suspension cultures (28 days), as previously
described by our group.19 In parallel, we performed forced
aggregation of cells without ECM as control (hereafter designated
as CM aggregates).
2.4. Characterization of hiPSC-CM Aggregates. 2.4.1. Cell
Viability, Beating Rate, and Metabolic Activity. The qualitative cell
viability was assessed by fluorescein diacetate (FDA Sigma-Aldrich),
and cell membrane integrity with the DNA-binding dye propidium
iodide (PI, Sigma-Aldrich), following the manufacturer instructions,
and the aggregates were visualized in a fluorescent microscope
(DMI600, Leica). The cells capable of accumulating the product of
FDA metabolization were stained fluorescent green and were
considered to be alive, while cells stained fluorescent red with PI
were considered dead. The average Feret diameter of cell aggregates
was estimated in ImageJ by analyzing several frames collected during
live imaging (at least 250 cell aggregates were analyzed per
condition). Also, cells were counted using Trypan Blue (Thermo
Fischer Scientific), as previously described.33
The beating rate was estimated by visualizing live-cell aggregates
under an inverted microscope (Olympus CKX31, Olympus) on a heat
plate (KL 1500 LCD, Leica) set at 37 °C; at least n = 3 cell aggregates
were analyzed per time point and condition.
The aggregate metabolic activity was quantified, as previously
described by our group,34 with PrestoBlue (Life Technologies),
following the manufacturer’s instructions.
2.4.2. Histology and Polarized Light Microscopy of hiPSC-CM
Aggregates. The histological sectioning of hiPSC-CM aggregates and
staining was done as described earlier (section 2.2.1). Samples were
either stained with H&E, MT, or Picro Sirius Red (PSR,
Polysciences), according to the manufacturer’s guidelines. PSR-
stained samples were visualized under a microscope with standard
bright field and polarization (Olympus BX41TF-P Polarized Light
Microscope, Olympus).
2.4.3. Scanning Electron Microscopy Analyzes of hiPSC-CM
Aggregates. The cell aggregate samples were collected and fixed with
4% (w/v) PFA (4 °C for 18 h) and rinsed with DPBS (RT for 10
min). Samples were dried in 12 mm adhesive carbon tape, sputter-
coated with a 15 nm Au/Pd film, and visualized in a ZEISS Auriga
Crossbeam SEM (5 keV).
2.4.4. Biochemical Analysis of hiPSC-CM Aggregates. Biochem-
ical analysis was carried out as indicated earlier (section 2.2.2). For
cell aggregates, data were expressed as the measured ECM component
mass normalized for measured dsDNA mass.
2.4.5. Immunofluorescence Microscopy of hiPSC-CM Aggre-
gates. The cell aggregates were harvested at day 28 and fixed in 4%
(w/v) PFA with 4% (w/v) sucrose in DPBS (RT for 20 min). The
samples were cryosectioned and the immunofluorescence performed
as previously described by our group.34 The primary antibodies used
were cardiac troponin T (cTnT) (Thermo Fisher Scientific, diluted
1:200), sarcomeric α-actinin (Sigma-Aldrich, diluted 1:200), collagen
I (abcam, diluted 1:100), α-smooth muscle actin (αSMA; Agilent
Technologies/DAKO, diluted 1:100), and vimentin (abcam, diluted
1:100). The secondary antibodies used were goat antirabbit IgG Alexa
Fluor 486 and goat antimouse Alexa Fluor 594 (all from Thermo
Fisher Scientific, diluted 1:500). The samples were visualized in a
confocal microscope (SP5 Live, Leica).
2.4.6. Flow Cytometry. The hiPSC-CM aggregates were collected
at day 28 and dissociated with TrypLE (37 °C for 5 min) for flow
cytometry analysis as previously described by our group.34 The
following conjugated antibodies were used: SIRPα/β (CD172a/b-PE,
BioLegend, diluted 1:20 in DPBS) and isotype control IgG2, k-PE
(BD Biosciences, diluted 1:5 in DPBS). Stained cell suspensions were
analyzed in a BD FACSCalibur cytometer (BD Biosciences), and the
analysis was performed with FlowJo software (TreeStar).
2.4.7. Gene Expression Analysis. Total RNA of aggregates
collected at days 11, 20, and 28 of culture was isolated, and the
gene expression analysis was performed by real-time quantitative
polymerase chain reaction (RT-qPCR) using TaqMan Gene
Expression Assays (MYH7, Hs01110632 m1; MYH6, Hs01101425
m1; MYL2, Hs00166405 m1; MYL7, Hs00221909 m1; TNNI3,
Hs00165957 m1; GAPDH, Hs99999905 m1; all from Thermo Fisher
Scientific), as previously described by our group.34 The data were
analyzed with log2-fold change normalized to day 11 of each
experimental condition and to GAPDH gene expression.
2.4.8. Transmission Electron Microscopy of hiPSC-CM Aggre-
gates. The samples were fixed in 2.5% (v/v) glutaraldehyde in DPBS
(RT for 20 min). The sample preparation and analysis were
performed as previously described.34 The transmission electron
microscopy (TEM) image analysis was done using ImageJ. Z-lines
corresponded to electron-dense regions, and the repeating units
between Z-lines were identified as the sarcomeres. The sarcomere
length was determined as the distance between consecutive parallel Z-
lines and Z-line length as the length of the electron-dense regions.
Sarcomere alignment was estimated based on the magnitude of angle
dispersion. Briefly, for frames containing several sarcomeres, the
angles of sarcomere edges were measured, the standard error of the
mean of angle measurements was computed, and data were presented
as the mean of those values. A low angle of dispersion is indicative of a
higher alignment degree.
2.4.9. Calcium Imaging. The calcium handling was evaluated with
the Fluo-4 Direct Calcium Assay Kit (Thermo Fisher Scientific), as
previously described.13,34 The results were analyzed using a custom
MATLAB script (MATLAB R2017b, Mathworks). The data were
normalized to baseline fluorescence (ΔF/F0), and each transient
calcium peak was analyzed for the following parameters: amplitude,
time to 80% decay, time to peak, maximal upstroke velocity, maximal
decay velocity, and cycle length, following the methodology described
before.13 In brief, calcium transient amplitude corresponds to the
maximal normalized fluorescent intensity; 80% decay time corre-
sponds to the time interval between maximal normalized fluorescent
intensity and 20% normalized fluorescent intensity during repolariza-
tion; time to peak was determined as the time interval between
minimum and maximal normalized fluorescent intensity during
depolarization; maximal upstroke and maximal decay velocities
correspond to the maximum magnitude of the tangent slopes to a
calcium transient during depolarization and repolarization, respec-
tively; cycle length was computed as the time interval a calcium
transient lasts.
2.5. Statistical Analysis. Data are shown as mean ± standard
deviation of independent measurements or assays (minimum of n =
3), and statistical analysis was performed using GraphPad Prism 7
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(GraphPad Software). The differences between experimental groups
were analyzed by Student’s t test or by one-way ANOVA. Post hoc
pairwise analysis was done using Tukey’s HSD test; p-values < 0.05
were considered significant for all statistical tests.
3. RESULTS
3.1. Processing and Characterization of Physically
Decellularized Human Myocardial Tissue. Adult myocar-
dial tissues derived from three healthy donors were assessed
histologically, showing typical myocardial architecture (i.e.,
muscle bundles) with the staining of traditional cellular and
ECM components such as nuclei and cytoplasm (HE), and
collagen (MT) (Figure 1a,b, left panels). Physical agents,
including temperature,35 force,36 and pressure,37,38 can be used
to effectively decellularize biological tissue. After thawing,
myocardial tissue pieces were snap-frozen in liquid nitrogen,
milled at room temperature, and freeze-dried overnight.
Cellular and matrisomal tissue organization were disrupted
throughout this process, creating tissue particles, designated as
ECM particles. By histology, loss of tissue morphological
architecture becomes evident (Figure 1a,b, right panels). The
efficiency of decellularization was evaluated through dsDNA
quantification assay. Native myocardial tissue contained 277.10
± 37.07 ng/mg wet tissue, and decellularized tissue had 67.87
± 22.77 ng/mg wet tissue of residual dsDNA (Figure 1c),
corresponding to a 75.5% reduction. H&E staining of ECM
particles showed little nuclei staining and cell debris after
decellularization (Figure 1a,b, right panels), supporting
dsDNA reduction. The impact of decellularization was also
evaluated concerning ECM composition by quantifying soluble
and insoluble collagen (hydroxyproline) and s-GAG before
and after physical treatment. Decellularization did not cause a
significant loss of soluble collagen (4.36 ± 0.31 μg/mg wet
tissue), insoluble collagen (6.88 ± 0.29 μg/mg wet tissue), and
s-GAG (5.23 ± 0.50 μg/mg wet tissue) (Figure 1c), even
though their organization within the ECM is not preserved
(Figure 1a,b, right panels).
SEM-EDS and AFM analyses of ECM particles suggested
that the decellularization protocol generated micrometric sized
particles, with a spherical-like shape (Figures 1d and S1) and
irregular surface topography (Figure 1e). ECM particles
showed a mean Feret diameter of 4.27 μm and low
polydispersity (Figure 1f), demonstrating the robustness of
the protocol in generating uniformly sized decellularized
particles. These ECM particles were used in the functionaliza-
tion of 3D hiPSC-CM aggregates, as described further.
3.2. Establishment of a Functionalized Cardiac
Aggregate Tissue Model. Scaffold-free 3D cardiac tissues,
such as hiPSC-CM aggregates, are powerful tools for high
throughput analysis, even though they do not yet fully
recapitulate the cardiac microenvironment. To improve their
physiological relevance, we incorporated human ECM
components in these microtissue models, namely micrometric
ECM particles isolated and processed from healthy adult
cardiac tissue. Briefly, early stage hiPSC-CM were harvested
from 2D contracting monolayers cultures at day 8 of
differentiation, as previously described by our group,19 and
aggregated using AgreeWell plates in the presence and absence
of 1% (w/v) ECM particles (corresponding to 3 ng ECM/
cell), hereafter designated as CM+ECM and CM groups,
Figure 1. Biochemical and structural characterization of physical-based decellularized human myocardial tissue. (a) Hematoxylin and Eosin (H&E)
and (b) Masson’s Trichrome (MT) staining for human myocardial native tissue and ECM particles. ECM particles were obtained by pooling
samples from the three tissue donors. Scale bars: 100 μm (native tissue, left panels) and 50 μm (ECM particles, right panels). (c) Double-stranded
DNA (dsDNA), sulfated glycosaminoglycans (s-GAG), soluble collagen, and insoluble collagen content on native tissue and ECM particles. The
average of the three myocardial tissue donors was used as a representative value for the component in the myocardium and normalized to tissue wet
weight (mg). Data are presented as mean ± standard deviation (SD) of three biological replicates (red dots corresponding to each tissue donor).
**p < 0.01; ns, not significant. (d) Scanning electron microscopy (SEM) of ECM particles. Scale bar: 10 μm. (e) Atomic force microscopy (AFM)
3D scanning image of ECM particles. (f) Histogram of Feret diameter distribution for ECM particles (n = 235 measurements). The blue line is a
log-normal curve fitting to the data.
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respectively (Figure 2a). Three days after forced aggregation,
cell aggregates were transferred to Erlenmeyer flasks and
cultured in agitated conditions for additional 17 days (total
culture time: 28 days) (Figure 2a).
Histological sections of cell aggregates confirmed the
incorporation of the ECM particles within CM+ECM
aggregates and their presence from the beginning to the end
of the 3D culture period (Figure 2b). CM+ECM aggregates
appear to be more compact, possibly owing to early lumen
filling by ECM particles. SEM analysis also revealed the
presence of ECM particles on the surface of CM+ECM
aggregates (Figure 2c). It is important to mention that these
ECM motifs are not present in the control group with CM-
only.
Biochemical analysis of aggregate content revealed higher
collagen and s-GAG concentration in CM+ECM aggregates
throughout culture time (Figure 2d). Collagen levels at day 11
in CM+ECM aggregates (0.95 ± 0.23 μg/ng of dsDNA) were
significantly higher than in CM aggregates (0.10 ± 0.02 μg/ng
of dsDNA), indicating incorporation of ECM particles within
Figure 2. ECM particles can be incorporated in a 3D cardiac aggregate model without compromising cell viability. (a) Experimental design: early
stage human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) were aggregated without (CM) or in combination with 1% (w/v)
(i.e., 3 ng/cell) ECM particles obtained from a physical-based decellularization method (CM+ECM). Aggregates were kept in Erlenmyer dynamic
culture for 17 days. (b) Hematoxylin and Eosin and Masson’s Trichrome staining for CM+ECM and CM aggregates at the beginning and end of
the culture period. (*) denotes ECM particles within CM+ECM aggregates. Scale bars: 50 μm. (c) Scanning electron microscopy (SEM) of CM
+ECM and CM aggregates at day 28 showing zoomed in sections detailing aggregate surface topography. White arrows point to ECM particles
present in the surface of a representative CM+ECM aggregate. Scale bars: 50 μm (left panels) and 5 μm (right panels). (d) Biochemical analysis of
total collagen (hydroxyproline) and sulfated glycosaminoglycan (s-GAG) content of CM+ECM and CM aggregates (n = 3 per time-point per
condition). Normalized to double stranded DNA weight. (e) Viability analysis of the CM+ECM and CM aggregates throughout culture time by
fluorescence microscopy, stained with fluorescein diacetate (FDA-live cells, green) and propidium iodide (PI-dead cells, red). Scale bars: 200 μm.
(f) Beating rate of CM+ECM and CM aggregates through culture time (n = 3 per time-point per condition). (g) Metabolic activity of CM+ECM
and CM aggregates throughout culture time (Presto-Blue assay), normalized by aggregate and to CM condition at day 11 (n = 3 per time point per
condition). Throughout, data are presented as mean ± SD *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns, not significant, determined by
one-way ANOVA followed by Tukey’s HSD test. CHIR, CHIR99021; AA, Ascorbic acid.
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aggregates and provided an initial collagen enriched micro-
environment (Figure 2d, upper panel). By day 28, no
significant changes in collagen concentration from initial
values were found in CM+ECM (0.94 ± 0.29 μg/ng of
dsDNA) and CM (0.28 ± 0.04 μg/ng of dsDNA) aggregates,
suggesting that cells did not significantly synthesize de novo
collagen in both culture regimens. Additionally, CM+ECM
aggregates maintained a significantly higher collagen content
than CM aggregates (Figure 2d, upper panel). Collagen
content within cell aggregates at day 28 was further evaluated
by immunofluorescence, revealing that CM+ECM aggregates
seem to have a distinct organization of collagen type I fibrils
(Figure S2a). PSR staining and polarized light microscopy
(PLM) also showed differential collagen fibril organization and
composition among the two groups (Figure S2b). Overall, CM
+ECM aggregates appear to contain a more substantial amount
of collagen type I (yellow) and collagen type III (green), which
are essential structural proteins that ensure tensile strength and
elasticity in the myocardium.
Although the incorporation of ECM particles did not
contribute to a s-GAG enrichment in hiPSC-CM aggregates
(0.77 ± 0.07 μg/ng of dsDNA and 0.67 ± 0.12 μg/ng of
Figure 3. Evidence of phenotypic, structural, and ultrastructural maturation in CM+ECM aggregates. (a) Immunofluorescence microscopy of CM
+ECM and CM aggregates cryosections at day 28. The cells were stained for sarcomeric structural proteins (cardiac troponin T (cTnT) and α-
actinin, red) and DAPI (blue). Zoomed-in sections show evidence of apparent typical cardiomyocyte striation. Scale bar: 50 μm; 10 μm (zoom).
(b) Percentage of SIRPα/β+ cells dissociated from CM+ECM and CM aggregates at day 28 (n > 2 per condition). (c) Gene expression data of CM
+ECM and CM aggregates throughout culture time for sarcomeric isoforms of mature and immature ventricular phenotype. The gene expression
was normalized to day 11 to each condition, and the mean fold change is presented (n = 3 per time point per condition). (d) Transmission electron
microscopy (TEM) images of CM+ECM and CM aggregates at day 28 showing aligned myofibrils, composed by sarcomeres with organized Z
lines, A-bands, and I-bands; cell junction (intercalated discs and gap junctions) between adjacent cardiomyocytes; abundant mitochondria. (*)
denotes mitochondria near sarcomeres. Scale bar: 500 nm. (e) Mean sarcomere length of CM+ECM and CM aggregates (n = 35 measurements per
condition). (f) Mean Z line length of CM+ECM and CM aggregates (n = 65 measurements per condition). (g) Sarcomere alignment was
determined by myofibril angle dispersion of CM+ECM and CM aggregates (n = 9 measurements per condition). Throughout, data are presented as
mean ± standard deviation (SD). *p < 0.05, **p < 0.01, ****p < 0.0001, ns, not significant, determined by Student’s t test.
ACS Applied Bio Materials www.acsabm.org Article
https://dx.doi.org/10.1021/acsabm.0c01490
ACS Appl. Bio Mater. 2021, 4, 1888−1899
1893
dsDNA in CM+ECM and CM groups, respectively), by day
28, CM+ECM had a significantly higher s-GAG concentration
(0.50 ± 0.12 μg/ng of dsDNA) than CM aggregates (0.07 ±
0.01 μg/ng of dsDNA) (Figure 2d, lower panel). By the end of
the culture period, CM aggregates had a steep decrease in s-
GAG content compared to its initial levels, whereas in CM
+ECM aggregates, s-GAG retention was substantially amelio-
rated. ECM particles appear to have improved s-GAG
maintenance and may be advantageous in maintaining
aggregate matrix integrity.
Our results confirmed that the functionalization with ECM
particles influenced neither cell viability, as confirmed by live/
dead staining throughout time (Figure 2e), nor the size of cell
aggregates that displayed very similar values of Ferret diameter
when compared to the CM group (Figure S3a). In fact, both
cell aggregate groups showed a tendency to reduce its size with
culture time that could be related to the shear stress
experienced in agitated cultures. In addition, CM+ECM
aggregates appear to become less spherical along time in
culture (d11:0.80 ± 0.13; d28:0.68 ± 0.12), which is less
noticeable in CM aggregates (d11:0.77 ± 0.14; d28:0.75 ±
0.11;) and with statistically significant differences among
models by the experimental end point (Figure S3b). CM
+ECM had a higher tendency to self-aggregate (Figure 2c,
upper panel), possibly motivated by the presence of ECM
particles, that could explain their less spherical appearance.
Synchronous spontaneous contractility was observed nearly
in all aggregates (Figure 2f). At day 11, CM+ECM and CM
aggregates presented a similar beating rate (respectively, 31.33
± 0.58 and 26.67 ± 4.73 beats min−1), but only CM+ECM
showed a moderate increase in beating rate along time in
culture (49.00 ± 2.00 beats min−1) that was statistically
different from the CM group at day 28 (Figure 2f).
Both CM+ECM and CM aggregates demonstrated similar
metabolic activity throughout culture (Figure 2g), even though
CM+ECM aggregates overall displayed a slightly higher
capacity to reduce resazurin along time in culture, relatively
to CM aggregates.
3.3. Phenotypic, Structural, and Ultrastructural
Features of Functionalized Cardiac Aggregates. By day
28, CM+ECM aggregates expressed cardiac troponin T
(cTnT) and sarcomeric α-actinin, with apparent features of
cardiomyocyte striation (Figure 3a). The expression for non-
myocyte cellular populations (stained for α-smooth muscle
actin and vimentin) was also detected by immunofluorescence
microscopy (Figure S4). Flow cytometry analysis confirmed
that the cell population was dominated by cardiomyocytes,
with a SIRPα/β+ cells percentage of 72.27 ± 11.99% in CM
+ECM aggregates and of 69.90 ± 12.73% in CM aggregates
Figure 4. Functional calcium handling of CM+ECM aggregates after 20 days of 3D culture. (a) Representative intracellular calcium transients of
CM+ECM and CM aggregates and following administration of 60 μM norepinephrine (Norepi). ΔF/F0, change in fluorescence intensity
concerning resting fluorescence intensity. (b−g) CM+ECM (light blue) and CM (dark blue) calcium handling kinetics obtained from the analysis
of the transients (n = 8 per condition), in the absence (full bars) and presence (stripped bars) of 60 μM norepinephrine: (b) amplitude, (c) time to
80% decay, (d) time to peak, (e) cycle length, (f) upstroke velocity, (g) decay velocity. Throughout, data are presented as mean ± standard
deviation (SD). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns, not significant, determined by one-way ANOVA followed by Tukey’s
HSD test.
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(Figure 3b), suggesting that ECM functionalization did not
compromise the cells’ phenotype and composition within the
aggregates.
In both cardiac aggregate models, there was a marked
change in the expression of genes associated with an adult-like
sarcomeric structural organization. CM+ECM and CM
aggregates showed an overtime switch in the expression of
ventricular sarcomeric fetal gene isoforms (decreased MYH6,
MYL7) to adult gene isoforms (increased MYH7, MYL2,
TNNI3) (Figure 3c). This change in the fetal gene program is
similar to what happens during cardiac muscle development in
utero, as to allow force generation with a higher economy of
energy consumption.39 Additionally, on day 28, expression of
MYH7, MYL2, and TNNI3 was higher in CM+ECM
aggregates than in control. This fact confirms not only the
advantage of a 3D setting to promote hiPSC-CM maturation19
but also that incorporation of ECM particles further improves
cardiac muscle structural maturity and preferential hiPSC-CM
specification toward a ventricular phenotype.
The ultrastructural assessment revealed both cardiac
aggregate models displayed sarcomeres composed of organized
Z-lines, A-bands, and I-bands, intercalated discs, and gap
junctions along electromechanically coupled cardiomyocytes,
and abundant mitochondria with distinct cristae preferentially
positioned near the contractile apparatus (Figure 3d). The
high density of mitochondria observed is consistent with
increased energetic workload needed for muscle contraction,
possibly as a result of a switch from a glycolytic to a more
oxidative metabolism,40 as we have previously shown for 3D
hiPSC-CM aggregates.19 The contractile machinery was more
developed in CM+ECM aggregates versus control, with longer
sarcomeres in length (respectively, 1.74 ± 0.22 μm and 1.58 ±
0.19 μm; Figure 3e) and width (respectively, 424.75 ± 164.39
nm and 261.38 ± 107.92 nm; Figure 3f). However, the average
sarcomere length of hiPSC-CM in CM+ECM aggregates is still
inferior to those found in adult cardiomyocytes41 (i.e., 2.2 μm).
Also, myofibril alignment was superior in the CM+ECM group
compared to CM aggregates, as shown by the significantly
lower values estimated for sarcomere angle dispersion
(respectively, 5.52 ± 2.21 and 10.39 ± 5.98; Figure 3g).
3.4. Calcium Handling of Functionalized Cardiac
Aggregates. Calcium handling in CM+ECM and CM
aggregates was assessed with a fluorescent calcium indicator,
enabling the detection of spontaneous calcium transients in
each cardiac contraction cycle (Videos S1, S2, S3, and S4).
Estimation of calcium kinetics’ parameters was done by
analyzing calcium transients, both in unstimulated conditions
and upon norepinephrine administration (Figure 4a). ECC
depends on trans-sarcolemmal calcium influx through L-type
Ca2+ channels and subsequent sarcoplasmic reticulum (SR)
calcium release.42 Unstimulated CM+ECM aggregates, com-
pared to unstimulated CM, exhibited significantly lower
transient amplitude (respectively, 1.29 ± 0.10 s and 2.13 ±
0.25 s; Figure 4b), relaxation time at 80% (respectively, 1.08 ±
0.40 s and 1.78 ± 0.17 s; Figure 4c), time to peak (respectively,
0.41 ± 0.12 s and 0.59 ± 0.04 s; Figure 4d), and cycle length
(respectively, 4.40 ± 0.83 s and 7.32 ± 1.65 s; Figure 4e).
These results indicate that ECM particles may have
contributed to a more organized ECC apparatus, allowing a
quicker sarcolemma depolarization, with a subsequently faster
SR calcium sequestration and sarcolemma repolarization. In
the immature hiPSC-CM trans-sarcolemmal influx of calcium
is the main driver in ECC due to an underdeveloped SR.43
Furthermore, a responsive β-adrenergic agonist receptor
system is both dependent upon L-type Ca2+ channel
functionality and SR calcium reserves,9,44 and it is a hallmark
of mature cardiac muscle. After being challenged with
norepinephrine, a β1-adrenergic agonist, both CM+ECM and
CM aggregates showed positive lusitropic and chronotropic
responses, with a decreased relaxation time at 80%
(respectively: 0.74 ± 0.05 s and 0.68 ± 0.04 s; Figure 4c),
and cycle length (2.36 ± 0.05 s and 1.94 ± 0.05 s, Figure 4e).
Also, when stimulated, CM+ECM versus CM aggregates
displayed a significantly higher peak amplitude (respectively,
2.89 ± 0.08 s and 1.95 ± 0.06 s; Figure 4b), maximal upstroke
velocity (respectively, 0.13 ± 0.01 s−1 and 0.09 ± 0.01 s−1;
Figure 4f), and maximal decay velocity (respectively, −0.06 ±
0.002 s−1 and −0.04 ± 0.003 s−1; Figure 4g), possibly
suggesting a more significant contribution of the SR in ECC,
even though we did not evaluate the functionality of this
organelle.
4. DISCUSSION
One of the goals of cardiac tissue engineering is to generate in
vitro heart-mimicking microtissues to study cardiac biology/
development, model disease, and for reliable drug screening.
To date, inducing maturation of hiPSC-CM is a challenge in
the field, limiting their use in clinical settings. The most
advanced strategies reported to date10,12,20 can emulate certain
cardiomyocyte features that become only evident in the
postnatal period. However, obtaining such mature EHT often
requires microfabricated platforms or biofabrication know-
how, as well as the need to adapt existing devices or tools to
evaluate tissue performance, rendering them poorly scalable for
high-throughput purposes. Also, the biomaterials typically used
to engineer these tissues do not fully resemble the cardiac
ECM. With this in mind, we took our established hiPSC-
derived cardiac aggregate model19 and developed a novel
aggregate microtissue that has improved cardiac mimicry by
incorporating a minimal quantity of ECM derived from adult
human cardiac tissue that had no use for transplantation
purposes (i.e., 3 ng ECM/cell). To understand the feasibility of
these aggregates’ functionalization, we pooled and processed
the tissue (in reduced amounts) to ameliorate limitations
regarding tissue heterogeneity and donor-to-donor variability.
This novel fully humanized cardiac aggregate retained key
ECM components throughout a 20-day 3D culture period and
showed improved structural maturity. Additionally, our
aggregates can be produced in a relatively cost-effective way
and are compatible to be scaled in GMP-compliant
bioprocesses.
Currently, organ/tissue decellularization is the best option
to obtain an ECM-like biomaterial due to the compositional
and structural complexity of biological matrices, even though
human tissue scarcity and heterogeneity might discourage such
an approach. Perfusion-decellularization of human hearts using
detergents and an endonuclease combination greatly reduced
dsDNA content, but proteomic analysis of the decellularized
scaffolds revealed an 89.14% reduction of the cardiac
proteome, with the maintenance of practically only ECM
protein families (collagens, laminins, fibrillins, and proteogly-
cans).31 Decellularizing human myocardial tissue with similar
chemical/enzymatic methods, that were previously proven
successful for animal tissue, is also subjected to patient-to-
patient variability.45 Our method relied purely on physical
approaches and was able to reduce tissue cellularity and
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preserve ECM composition in a reproducible and consistent
way among donors. Soluble components, such as s-GAG and
soluble collagen, which tend not to be fully preserved in
detergent/enzymatic-based decellularization protocols,46 were
retained with our methodology. Further optimizations to our
method may be necessary if complete elimination of cells is
required. Also, tissue architecture was thoroughly disrupted,
making these decellularized (micrometric) scaffolds unsuitable
for tissue bioengineering. However, ECM biomaterials are
versatile and have other applications that do not require
maintaining scaffold architectural integrity, as we have shown
here and others elsewhere. For instance, ECM can be broken
down, solubilized, and then assembled into nanofibrous
hydrogels47 that are useful to restore myocardium mechanical
integrity after infarction,48 or even as a functional element in
advanced biofabrication methodologies to create complex
biological tissues.49,50
ECM was successfully incorporated in a 3D cardiac
aggregate model, contributing to a microenvironment richer
in ECM components without compromising cell viability and
metabolic activity. Noteworthy, we were able to weigh the
ECM particles accurately and include them in the forced
aggregation step, within the AgreeWells, with a ratio of 3 ng of
ECM per cell used. In this process, some of the ECM is lost,
but we ensure that we have ECM particles within the
aggregates by applying this ECM/cell ratio. Notably, CM
+ECM aggregates retained these ECM components until the
end of the culture period. Our aggregates presented a distinct
collagen network and were able to better retain soluble
components, such as s-GAG, throughout culture. Dynamic
culture conditions have been described to promote s-GAG
flushing into the medium, resulting in tissue constructs with
poor s-GAG content.51,52 We hypothesize an initial ECM
enrichment within the aggregate might have contributed in
improving s-GAG retention by counteracting shear forces that
might be prevalent in dynamic cultures. Also, it is known that
the interaction between collagens and s-GAG can mediate
tissues’ integrity and resilience, and when an imbalance
between both components happens, it is common to
experience tissue dysfunction.27 Since CM+ECM aggregates
had a superior collagen content throughout culture and these
collagens were differentially organized within the aggregate,
this improved structural meshwork might have served as
anchoring points to s-GAG (and possible other soluble
components or signaling molecules), thus overall improving
microtissue matrisomal integrity.
Previous studies have identified the ECM as a relevant
contributor in cardiomyocyte differentiation29 and matura-
tion.30 Here, we described that human cardiac ECM plays a
role in hiPSC-CM structural maturation. Our CM+ECM
aggregates outperformed CM aggregates in several ways. In
particular, CM+ECM aggregates had a higher gene expression
of mature ventricular sarcomeric isoforms and longer
sarcomeres with a higher degree of alignment. A more
organized contractile apparatus ultimately improved calcium
handling, with a noticeably quicker ECC and improved
response upon a β1-adrenergic challenge. These differences
may suggest an ECM-enriched microenvironment is positively
stimulating hiPSC-CM. Even though our cardiac aggregates
were not actively being electromechanically stimulated (as it is
common for EHT in elastomeric pillars), evidence suggests
passive stretching and resistance to construct contraction
imposed by the ECM may be sufficient to mechanically
stimulate the cells.53 Hence, we can state that this particle size
was appropriate to allow ECM incorporation within the
aggregates, stimulating the cells and promoting maturation,
without compromising their 3D structure. We have also
observed that our CM+ECM aggregates had a moderate
increase in beating frequency throughout culture. Automaticity
is a hallmark of hiPSC-CM electrophysiological immaturity;54
however, early loss of spontaneous contraction may negatively
impact structural maturation. In fact, overexpression of KCNJ2
eliminated the phase 4-like depolarization of hESC-CM and
ceased their spontaneous firing but led to the downregulation
of the contractile apparatus.55 Therefore, during maturation,
active contraction motivated by an increasing beating
frequency may be beneficial to first induce cytoskeleton
reorganization, as we verified in our ECM functionalized
aggregates, and loss of automaticity later on may improve
electrophysiological maturity. As a matter of fact, the fetal heart
has a beating frequency superior to the adult heart56 (i.e., 2−3
Hz versus 1 Hz), which has inspired the development of
supraphysiological pacing regimens to promote cardiac muscle
structural maturation.10−12 Even though our CM+ECM
aggregates did not develop features that are hallmarks of an
adult-like ECC apparatus, such as T-tubulation and a positive
FFR, it has been documented that aggregates can effectively be
electrically stimulated in microbioreactor systems.57 Combin-
ing both an ECM-enriched environment, as we have described,
and providing electrical stimulation could further improve our
aggregate performance and its predictive capacity for precision
medicine applications.
Cardiac aggregates present several limitations relative to
some EHT models, as they do not allow precise measurement
of contractile force and cannot fully recreate the aligned
bundle-like appearance of cardiac muscle. Nonetheless, due to
their simplicity and high-throughput compatibility, we envision
microtissues with improved cardiac mimicry, like the one
presented here, could still be powerful tools for drug
screening/discovery and disease modeling. In fact, recent
studies have reported cardiac microtissues/organoids as
reliable platforms in recapitulating heart disease, either by
modulating environmental factors in healthy microtissues58 or
engineering patient-specific microtissues carrying disease
susceptibilities.14 As ECM dysfunction and remodeling are
hallmarks of postmyocardial infarction injury,27 it would be
relevant to investigate if hiPSC-CM would behave differently if
aggregated with pathological human ECM. A recent EHT
grown from hiPSC-CM in combination with ECM decellular-
ized from hypertrophic cardiomyopathy porcine tissue biopsies
presented abnormal contractile mechanics and calcium
handling.59 Validating these results in our humanized aggregate
model could further validate its use in disease modeling as well
as contribute for a better understanding of the ECM’s role in
heart disease to guide the development of innovative cardiac
therapies.
5. CONCLUSION
In the current work, we demonstrated that human cardiac
myocardial ECM can be decellularized, isolated, fragmented,
and, for the first time, successfully incorporated in 3D hiPSC-
CM aggregates. The constructs denoted high cell viability and
metabolic activity throughout 20 days in agitated culture
conditions. The incorporation of the ECM was possible in
microtissues by disrupting human cardiac tissue architecture
through a physical decellularization approach, even though this
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did not result in substantial loss of its functional components.
We demonstrate that human cardiac ECM promotes the
phenotypic, structural, and ultrastructural maturation of
cardiomyocytes, which further improves calcium handling.
We believe that we developed an innovative methodology
using cryomilled human ECM to mature hiPSC-CM within 3D
aggregates. This approach has several advantages compared
with hydrogels with solubilized ECM, which include the
maintenance of the cardiac tissue’s micromechanical and
compositional properties. Hence, the knowledge generated
with this work delivers important insights to streamline the
application of more physiologically relevant hiPSC-CM-based
tissues to be used in cardiac tissue engineering applications.
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Tecnologia e Ensino Superior, through national funds is
acknowledged; Funding from INTERFACE Programme,
through the Innovation, Technology and Circular Economy
Fund (FITEC), is gratefully acknowledged; and EU-funded
projects BRAV3 (H2020, ID:874827) and ERAatUC (ref.
669088). HVA, AFL, and DS were financed by FCT Grants
SFRH/BPD/120595/2016 and PD/BD/139078/2018 and
PD/BD/106051/2015, respectively.
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
The authors acknowledge Joana I. Almeida, from iBET, for the
support in flow cytometry and qRT-PCR analyses; Pedro Díaz-
Payno and Daniel Kelly, from Trinity College Dublin, for their
support in PLM imaging; A. L. Sousa and E. M. Tranfield from
the Electron Microscopy Facility at the Instituto Gulbenkian
de Cien̂cia (IGC) for the technical support in TEM; G.
Martins from the Advanced Imaging Facility at IGC for the
technical support in immunofluorescence microscopy; and the
Flow Cytometry and Histopathology units at IGC.
■ REFERENCES
(1) Bergmann, O.; Bhardwaj, R. D.; Bernard, S.; Zdunek, S.;
Barnabé-Heide, F.; Walsh, S.; Zupicich, J.; Alkass, K.; Buchholz, B. A.;
ACS Applied Bio Materials www.acsabm.org Article
https://dx.doi.org/10.1021/acsabm.0c01490
ACS Appl. Bio Mater. 2021, 4, 1888−1899
1897
Druid, H.; Jovinge, S.; Frisén, J. Evidence for Cardiomyocyte Renewal
in Humans. Science (Washington, DC, U. S.) 2009, 324 (5923), 98−
102.
(2) Banyasz, T.; Lozinskiy, I.; Payne, C. E.; Edelmann, S.; Norton,
B.; Chen, B.; Chen-Izu, Y.; Izu, L. T.; Balke, C. W. Transformation of
Adult Rat Cardiac Myocytes in Primary Culture. Exp. Physiol. 2008,
93 (3), 370−382.
(3) Fischer, C.; Milting, H.; Fein, E.; Reiser, E.; Lu, K.; Seidel, T.;
Schinner, C.; Schwarzmayr, T.; Schramm, R.; Tomasi, R.; Husse, B.;
Cao-Ehlker, X.; Pohl, U.; Dendorfer, A. Long-Term Functional and
Structural Preservation of Precision-Cut Human Myocardium under
Continuous Electromechanical Stimulation in Vitro. Nat. Commun.
2019, 10 (1), 1−12.
(4) Shiba, Y.; Gomibuchi, T.; Seto, T.; Wada, Y.; Ichimura, H.;
Tanaka, Y.; Ogasawara, T.; Okada, K.; Shiba, N.; Sakamoto, K.; Ido,
D.; Shiina, T.; Ohkura, M.; Nakai, J.; Uno, N.; Kazuki, Y.; Oshimura,
M.; Minami, I.; Ikeda, U. Allogeneic Transplantation of IPS Cell-
Derived Cardiomyocytes Regenerates Primate Hearts. Nature 2016,
538, 388−391.
(5) Burridge, P. W.; Li, Y. F.; Matsa, E.; Wu, H.; Ong, S. G.; Sharma,
A.; Holmström, A.; Chang, A. C.; Coronado, M. J.; Ebert, A. D.;
Knowles, J. W.; Telli, M. L.; Witteles, R. M.; Blau, H. M.; Bernstein,
D.; Altman, R. B.; Wu, J. C. Human Induced Pluripotent Stem Cell-
Derived Cardiomyocytes Recapitulate the Predilection of Breast
Cancer Patients to Doxorubicin-Induced Cardiotoxicity. Nat. Med.
2016, 22 (5), 547−556.
(6) Yazawa, M.; Hsueh, B.; Jia, X.; Pasca, A. M.; Bernstein, J. A.;
Hallmayer, J.; Dolmetsch, R. E. Using Induced Pluripotent Stem Cells
to Investigate Cardiac Phenotypes in Timothy Syndrome. Nature
2011, 471 (7337), 230−236.
(7) Burridge, P. W.; Matsa, E.; Shukla, P.; Lin, Z. C.; Churko, J. M.;
Ebert, A. D.; Lan, F.; Diecke, S.; Huber, B.; Mordwinkin, N. M.;
Plews, J. R.; Abilez, O. J.; Cui, B.; Gold, J. D.; Wu, J. C. Chemically
Defned Generation of Human Cardiomyocytes. Nat. Methods 2014,
11 (8), 855−860.
(8) Veerman, C. C.; Kosmidis, G.; Mummery, C. L.; Casini, S.;
Verkerk, A. O.; Bellin, M. Immaturity of Human Stem-Cell-Derived
Cardiomyocytes in Culture: Fatal Flaw or Soluble Problem? Stem
Cells Dev. 2015, 24, 1035.
(9) Mannhardt, I.; Breckwoldt, K.; Letuffe-Brenier̀e, D.; Schaaf, S.;
Schulz, H.; Neuber, C.; Benzin, A.; Werner, T.; Eder, A.; Schulze, T.;
Klampe, B.; Christ, T.; Hirt, M. N.; Huebner, N.; Moretti, A.;
Eschenhagen, T.; Hansen, A. Human Engineered Heart Tissue:
Analysis of Contractile Force. Stem Cell Rep. 2016, 7 (1), 29−42.
(10) Ronaldson-Bouchard, K.; Ma, S. P.; Yeager, K.; Chen, T.; Song,
L. J.; Sirabella, D.; Morikawa, K.; Teles, D.; Yazawa, M.; Vunjak-
Novakovic, G. Advanced Maturation of Human Cardiac Tissue
Grown from Pluripotent Stem Cells. Nature 2018, 556, 239.
(11) Nunes, S. S.; Miklas, J. W.; Liu, J.; Aschar-Sobbi, R.; Xiao, Y.;
Zhang, B.; Jiang, J.; Massé, S.; Gagliardi, M.; Hsieh, A.; Thavandiran,
N.; Laflamme, M. A.; Nanthakumar, K.; Gross, G. J.; Backx, P. H.;
Keller, G.; Radisic, M. Biowire: A Platform for Maturation of Human
Pluripotent Stem Cell-Derived Cardiomyocytes. Nat. Methods 2013,
10 (8), 781−787.
(12) Zhao, Y.; Rafatian, N.; Feric, N. T.; Cox, B. J.; Aschar-Sobbi, R.;
Wang, E. Y.; Aggarwal, P.; Zhang, B.; Conant, G.; Ronaldson-
Bouchard, K.; Pahnke, A.; Protze, S.; Lee, J. H.; Davenport Huyer, L.;
Jekic, D.; Wickeler, A.; Naguib, H. E.; Keller, G. M.; Vunjak-
Novakovic, G.; Broeckel, U.; Backx, P. H.; Radisic, M. A Platform for
Generation of Chamber-Specific Cardiac Tissues and Disease
Modeling. Cell 2019, 176 (4), 913−927.
(13) Abecasis, B.; Gomes-Alves, P.; Rosa, S.; Gouveia, P. J.; Ferreira,
L.; Serra, M.; Alves, P. M. Unveiling the Molecular Crosstalk in a
Human Induced Pluripotent Stem Cell-Derived Cardiac Model.
Biotechnol. Bioeng. 2019, 116, 1245.
(14) Giacomelli, E.; Meraviglia, V.; Campostrini, G.; Cochrane, A.;
Cao, X.; van Helden, R. W. J.; Krotenberg Garcia, A.; Mircea, M.;
Kostidis, S.; Davis, R. P.; van Meer, B. J.; Jost, C. R.; Koster, A. J.;
Mei, H.; Míguez, D. G.; Mulder, A. A.; Ledesma-Terrón, M.;
Pompilio, G.; Sala, L.; Salvatori, D. C. F.; Slieker, R. C.; Sommariva,
E.; de Vries, A. A. F.; Giera, M.; Semrau, S.; Tertoolen, L. G. J.;
Orlova, V. V.; Bellin, M.; Mummery, C. L. Human-IPSC-Derived
Cardiac Stromal Cells Enhance Maturation in 3D Cardiac Micro-
tissues and Reveal Non-Cardiomyocyte Contributions to Heart
Disease. Cell Stem Cell 2020, 26, 862.
(15) Correia, C.; Koshkin, A.; Duarte, P.; Hu, D.; Teixeira, A.;
Domian, I.; Serra, M.; Alves, P. M. Distinct Carbon Sources Affect
Structural and Functional Maturation of Cardiomyocytes Derived
from Human Pluripotent Stem Cells. Sci. Rep. 2017, 7 (1), 8590.
(16) Hu, D.; Linders, A.; Yamak, A.; Correia, C.; Kijlstra, J. D.;
Garakani, A.; Xiao, L.; Milan, D. J.; van der Meer, P.; Serra, M.; Alves,
P. M.; Domian, I. J. Metabolic Maturation of Human Pluripotent
Stem Cell-Derived Cardiomyocytes by Inhibition of HIF1α and
LDHA. Circ. Res. 2018, 123 (9), 1066−1079.
(17) Yang, X.; Rodriguez, M.; Pabon, L.; Fischer, K. A.; Reinecke,
H.; Regnier, M.; Sniadecki, N. J.; Ruohola-Baker, H.; Murry, C. E.
Tri-Iodo-l-Thyronine Promotes the Maturation of Human Cardio-
myocytes-Derived from Induced Pluripotent Stem Cells. J. Mol. Cell.
Cardiol. 2014, 72, 296.
(18) Parikh, S. S.; Blackwell, D. J.; Gomez-Hurtado, N.; Frisk, M.;
Wang, L.; Kim, K.; Dahl, C. P.; Fiane, A.; Tønnessen, T.; Kryshtal, D.
O.; Louch, W. E.; Knollmann, B. C. Thyroid and Glucocorticoid
Hormones Promote Functional T-Tubule Development in Human-
Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Circ. Res.
2017, 121 (12), 1323−1330.
(19) Correia, C.; Koshkin, A.; Duarte, P.; Hu, D.; Carido, M.;
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